<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-6914</journal-id>
<journal-title><![CDATA[Revista Onconews]]></journal-title>
<abbrev-journal-title><![CDATA[Revista Onconews]]></abbrev-journal-title>
<issn>2183-6914</issn>
<publisher>
<publisher-name><![CDATA[Associação de Enfermagem Oncológica Portuguesa (AEOP)]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-69142020000200018</article-id>
<article-id pub-id-type="doi">10.31877/on.2020.41.02</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Extravasamento de manitol: um estudo de caso prático]]></article-title>
<article-title xml:lang="en"><![CDATA[Manitol extravasation: nursing case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Almeida]]></surname>
<given-names><![CDATA[Ana Catarina Vieira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Salvado]]></surname>
<given-names><![CDATA[Heidi de Jesus Faísca]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[Liliana Dias]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,IPO Lisboa Pneumologia ]]></institution>
<addr-line><![CDATA[Lisboa ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>12</month>
<year>2020</year>
</pub-date>
<numero>41</numero>
<fpage>18</fpage>
<lpage>24</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-69142020000200018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-69142020000200018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-69142020000200018&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo Diversos fármacos têm o potencial de causar danos nos tecidos se ocorrer extravasamento. A gravidade do extravasamento e a dimensão da lesão estão dependentes de inúmeros fatores, tais como a dose do medicamento, a sua concentração, local de administração e tempo de exposição ao mesmo. A prevenção é a forma mais eficaz de gestão do extravasamento. Perante a ocorrência de extravasamento torna-se crucial adotar um conjunto de medidas/protocolo atempados e adequados com o intuito de prevenir sequelas a longo prazo. As lesões por extravasamento, não relacionadas com a administração de quimioterapia (QT), mais frequentemente reportadas são causadas por soluções hiperosmolares e agentes vasopressores. A hialuronidase é o antídoto dos fármacos hiperosmolares sendo a sua administração fundamental na prevenção de danos nos tecidos decorrentes do extravasamento. Importa, assim, conhecer os princípios gerais que devem nortear a abordagem desta forma de iatrogenia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Several drugs have the potential to cause tissue damage if extravasation occurs. The severity of extravasation and the size of the lesion are dependent on a number of factors such as the dose of the drug, its concentration, place of administration and length of drug exposure. Prevention is the most effective form of management in case of an extravasation/ leakage. If an overflow occurs it is crucial to adopt a suitable set of measures/protocol not only to manage the overflow but to minimize the resulting damage. The most frequently reported extravasation lesions unrelated to chemotherapy administration are caused by hyperosmolar solutions and vasopressor agents. Hyaluronidase is the antidote to hyperosmolar drugs and its administration is important in preventing tissue damage due to extravasation.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Extravasão vesicante]]></kwd>
<kwd lng="pt"><![CDATA[manitol]]></kwd>
<kwd lng="pt"><![CDATA[enfermagem]]></kwd>
<kwd lng="pt"><![CDATA[hialorunidase]]></kwd>
<kwd lng="en"><![CDATA[Vesicant extravasation]]></kwd>
<kwd lng="en"><![CDATA[mannitol]]></kwd>
<kwd lng="en"><![CDATA[nursing]]></kwd>
<kwd lng="en"><![CDATA[hyaluronidase]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<collab>DIREÇÃO GERAL DA SAÚDE</collab>
<source><![CDATA[Programa Nacional para as Doenças Oncológicas]]></source>
<year>2017</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
<publisher-name><![CDATA[DGS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="book">
<collab>NATIONAL CANCER INSTITUTE</collab>
<source><![CDATA[Types of Cancer Treatment]]></source>
<year>2018</year>
<publisher-loc><![CDATA[United States ]]></publisher-loc>
<publisher-name><![CDATA[NCI]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DEVAUD]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[SIGRIST]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[ZAUGG]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proposition d&#8217;une marche à suivre pour la gestion et la prévention d&#8217;extravasation d&#8217;agents non cytotoxiques]]></article-title>
<source><![CDATA[Pharmactuel]]></source>
<year>2012</year>
<volume>45</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>132-6</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<collab>ESMO Guidelines Working Group</collab>
<article-title xml:lang=""><![CDATA[Management of chemotherapy extravasation. ESMO-EONS Clinical Practice Guidelines]]></article-title>
<source><![CDATA[Annals of Oncology]]></source>
<year>2012</year>
<volume>23</volume>
<numero>^sSupplement 7</numero>
<issue>^sSupplement 7</issue>
<supplement>Supplement 7</supplement>
<page-range>vii167-73</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[COYLE]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[GRIFFIE]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[CZAPLEWSKI]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eliminating extravasation events: A multidisciplinary approach]]></article-title>
<source><![CDATA[Journal of Infusion Nursing]]></source>
<year>2014</year>
<volume>37</volume>
<page-range>157-64</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCHULMEISTER]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vesicant chemotherapy extravasation management]]></article-title>
<source><![CDATA[British Journal of Nursing]]></source>
<year>2011</year>
<volume>20</volume>
<page-range>6-12</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SCHULMEISTER]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extravasation management: clinical update]]></article-title>
<source><![CDATA[Seminars in Oncology Nursing]]></source>
<year>2011</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>82-90</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[SALDANHA]]></surname>
<given-names><![CDATA[MJM]]></given-names>
</name>
</person-group>
<source><![CDATA[Normas de atuação em caso de extravasão de medicamentos intravenosos vesicantes não citotóxicos]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[EDWARDS]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[SAMUELS]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[FU]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Forearm compartment syndrome from intravenous mannitol extravasation during general anesthesia]]></article-title>
<source><![CDATA[Anesthesia &amp; Analgesia]]></source>
<year>2003</year>
<volume>97</volume>
<page-range>1195-207</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<collab>EUROPEAN ONCOLOGY NURSING SOCIETY</collab>
<article-title xml:lang=""><![CDATA[European Oncology Nursing Society extravasation guidelines]]></article-title>
<source><![CDATA[European Journal of Oncology Nursing]]></source>
<year>2008</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>357-61</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[KUMAR]]></surname>
<given-names><![CDATA[M. M.]]></given-names>
</name>
<name>
<surname><![CDATA[SPRUNG]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The use of hyaluronidase to treat mannitol extravasation]]></article-title>
<source><![CDATA[Anesthesia &amp; Analgesia]]></source>
<year>2003</year>
<volume>97</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1199-200</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LAWSON]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[BRADY]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[MAHMOUD]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of highly concentrated dextrose solution (50% dextrose) extravasation and treatment - a clinical report]]></article-title>
<source><![CDATA[American Journal of Emergency Medicine]]></source>
<year>2013</year>
<volume>31</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>886.e3-5</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LE]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[PATEL]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Extravasation of noncytotoxic drugs: A review of the literature]]></article-title>
<source><![CDATA[Annals of Pharmacotherapy]]></source>
<year>2014</year>
<volume>48</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>870-86</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="book">
<collab>UNIVERSITY OF WISCONSIN HOSPITALS AND CLINICS AUTHORITY</collab>
<source><![CDATA[Guideline for Non-Chemotherapeutic Agents: Prevention and Treatment of Chemical Phlebitis and Extravasation of Peripherally Administered Non-chemotherapeutic Agents - Adult/Pediatric-Inpatient Clinical Practice Guideline]]></source>
<year>2015</year>
<publisher-name><![CDATA[UWHealth]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[FRIEDRICH]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[SHIN]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Management of forearm compartment syndrome]]></article-title>
<source><![CDATA[Critical Care Nursing Clinics of North America]]></source>
<year>2012</year>
<volume>24</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>261-74</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DOELLMAN]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[HADAWAY]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[BOWE-GEDDES]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Infiltration and extravasation: update on prevention and management]]></article-title>
<source><![CDATA[Journal of Infusion Nursing]]></source>
<year>2009</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>203-11</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
